SCHEMBL26674340

SCHEMBL26674340

CC(C)c1ccc2ccn(CC(C)(C)C)c2c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 3/20 0.51
HTR2C P28335 10/20 0.44
HTR2A P28223 9/20 0.44
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
HPGD P15428 1/20 0.36
APOBEC3A P31941 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
HTR2B P41595 1/20 0.35
HTR1D P28221 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26674331 0.80 HTR7 (0.53) HTR7HTR2CHTR2ACYP1A2CYP3A4
SCHEMBL24143572 0.78 HTR2C (0.57) HTR7HTR2CHTR2ACYP1A2
SCHEMBL24144443 0.77 HTR7 (0.63) HTR7HTR2CHTR2A
SCHEMBL25154223 0.76 HTR7 (0.56) HTR7HTR2CHTR2AL3MBTL1HTR1D
SCHEMBL18654019 0.75 HTR7 (0.42) HTR7HTR2CHTR2A
SCHEMBL20614497 0.75 HTR1D (0.62) HTR7HTR2CHTR2AHTR1D
SCHEMBL26674263 0.75 HTR2C (0.50) HTR7HTR2CHTR2ACYP1A2CYP3A4
SCHEMBL24943632 0.75 HTR7 (0.42) HTR7HTR2CHTR2AKDM4EALDH1A1
SCHEMBL24144949 0.74 HTR7 (0.53) HTR7HTR2CHTR2A
SCHEMBL18085895 0.73 HTR7 (0.47) HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339886-A1 REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-10-26 US disclosed
US-20230339886-A1 REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339886-A1 REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS NR1H2, NR1H3, NR1D1 HTR7 3434/4885HTR2C 3626/4885HTR2A 3630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.